Connect Sign In
ARUP announced the availability to clients nationwide of a combined test to detect and differentiate COVID-19, influenza, and respiratory syncytial virus (RSV).
ARUP Laboratories now offers testing to detect the virus that causes COVID-19 using saliva specimens. The molecular diagnostic test is available with preapproval to ARUP clients nationwide.
As a national EAP program to deliver COVID-19 convalescent plasma to hospitalized patients with COVID-19 concludes, researchers are transitioning to multicenter randomized clinical trials.
When supplies of a critical component of kits used to collect specimens for COVID-19 testing suddenly grew scarce, scientists at ARUP worked to formulate an alternative.
Self-collected saliva and deep nasal swabs collected by healthcare providers are equally effective for detecting SARS-CoV-2, the virus that causes COVID-19, according to a new study.
While many companies are laying off or furloughing employees due to the COVID-19 pandemic, ARUP is experiencing a hiring surge as the company continues to expand its COVID-19 testing capacity.
ARUP implemented numerous safety protocols when the pandemic began. Now, as cases of COVID-19 surge, the company is facing new challenges in preventing the spread of the virus among its employees.
ARUP Laboratories’ Tracy George, MD, an internationally recognized expert on mast cell disorders, was recently appointed president of the International Society for Laboratory Hematology (ISLH).
When hospitals began postponing elective surgeries, directors of pathology training programs scrambled to adapt so that residents and fellows could still receive the instruction they needed.
Just 1% of residents in four Utah counties have antibodies to SARS-CoV-2, a prevalence rate below that of many other communities in the U.S., according to preliminary results of the Utah HERO project.
